期刊文献+

非小细胞肺癌中BRCA1、ERCC1和EGFR的表达及临床病理意义 被引量:9

EXPRESSION AND CLINICOPATHOLOGICAL SIGNIFICANCE OF BRCA1、ERCC1 AND EGFR IN NON-SMALL LUNG CARCINOMA
原文传递
导出
摘要 目的研究BRCA1、ERCC1和EGFR在非小细胞肺癌(NSCLC)中的表达及预后意义。方法用免疫组化ElivisionTM plus法,检测77例非小细胞肺癌和6例癌旁组织中BRCA1、ERCC1和EGFR的表达情况。结果非小细肺癌中BRCA1、ERCC1、EGFR在癌中的表达显著高于癌旁组织,且在癌中的表达具有正相关性;BRCA1、ERCC1在不同病理类型和分期中表达均无差异;BRCA1高表达组的生存期明显小于低表达组;EGFR有淋巴结转移组阳性表达率明显高于无淋巴结转移组;应用铂类药物化疗ERCC1低表达组的生存期明显明显长于高表达组。结论在NSCLC中BRCA1、ERCC1、EGFR在肺癌中的表达显著高于癌旁组织,BRCA1高表达组的生存期明显小于低表达组,EGFR高表达可能促进肿瘤的侵袭和转移,ERCC1是铂类治疗独立的预后因素,三项抗体的检测与预后和临床用药密切相关。 Objective To investigated the expressions of BRCA1、ERCC1 and EGFR in patients with non-small cell lung carcinoma(NSCLC) as well as their clinical prognostic significance.Methods The expression of BRCA1、ERCC1、EGFR in 77 cases of NSCLC and in 6 cases of adjacent normal lung tissue samples of lung carcinoma by immunohistochemistry with ElivisionTM plus method.Results The expression levels of BRCA1、ERCC1 and EGFR were significantly higher in lung cancer tissues than that in adjacent normal lung tissues.There were significant correlations between intratumoral expression of BRCA1、ERCC1 and EGFR.The expression of BRCA1 and ERCC1 had no difference between different pathological classification and clinical TNM stages.The patients with high expression of BRCA1 had significant shorter survival time than those with low expression of BRCA1.Overexpression of EGFR in NSCLCS was related to lymph node metastasis(P〈0.05).The patients with low expression of ERCC1 had significant longer survival time than those with high expression.Conclusion The expression levels of ERCC1,BRCA1 and EGFR are significantly higher in lung cancer tissues than that of adjacent normal lung tissues.The patients with high expression of BRCA1 had significant shorter survival time than those with low expression.In NSCLC,the EGFR may play an important role in papillary thyroid cancer progression.The difference expression of ERCC1 might be a molecule marker of chemotherapy sensitivity in NSCLC patients with cisplatin-based chemotherapy.Detection of BRCA1、ERCC1、EGFR is valuable for clinical and evaluation of prognosis for non-small cell lung carcinoma.
出处 《中国煤炭工业医学杂志》 2010年第7期963-966,共4页 Chinese Journal of Coal Industry Medicine
关键词 非小细胞肺癌 BRCA1 ERCC1 EGFR 免疫组织化学 Non-small cell lung carcinoma BRCA1 ERCC1 EGFR immunohistochemistry
  • 相关文献

参考文献18

  • 1Mountan CF. Revisions in the International system for staging lung cancer[J]. Chest,1997,111:1710 - 1717.
  • 2Yang Q, Sakurai T, Mori I, et al. Prognostic significance of BRCA1 expression in Japanese sporadic breast carcinomas [J]. Cancer, 2001,92 : 54 - 60.
  • 3Chen BK, Ohtsuki Y, Furihata M, et al. Cooverexpression of p53 protein and epidermal growth factor receptor in human papillary thyroid carcinomas correlated with lymph node metastasis, tumor size and elinicopathologic stage[J]. Int J Oncol, 1999,15 : 893 - 898.
  • 4Reginald V, Lord N, Brabender J, et al. ERCC1 expression correlates with prdonged survival after cisplatin plus gemcitahine chemotherapy in non - small cell lung cancer[J]. Ctin Cancer Res,2007,8:2286 - 2291.
  • 5Schiller JH, Harringto D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non- small cell lung cancer[J]. N Engl J Med,2002,346 : 92 - 98.
  • 6Miki Y, Swensen J, Shattuck- Eidens D, et al. A strong candidate for the breast and ovarian cancer susceptibility gene BRCAI[J]. Science, 1994,266:66 - 71.
  • 7Bergman A,Flodin A, Engwall Y, et al. A high frequency of germline BRCA1/2 mutations in western Sweden detected with complementary screening techniques[J]. Familial Cancer,2005,4:89 - 96.
  • 8Taron M, Rosell R, Felip E, et al. BRCAlmRNA expression levels as an indicator of chemoresistance in lung cancer[J]. Hum Mol Genel, 2004,13 : 2443 - 2449.
  • 9Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancer[J]. Int J Cancer,2006,118;257 - 262.
  • 10Normanno N, De Luca A, Bianco C, et al. Epidermal growth factor receptor(EGFR) signaling in cancer[J]. Gene, 2006, 316:2 - 16.

二级参考文献23

  • 1韩宇,徐建明,宋三泰.IRESSA治疗晚期非小细胞肺癌的研究进展[J].中国肿瘤临床,2006,33(2):111-114. 被引量:2
  • 2Siegel-Lakhai WS, Beijnen JH, ScheUens JH. Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa). Oncologist, 2005, 10: 579 - 589.
  • 3Hirsch FR, Witta S. Biomarkers for prediction of sensitivity to EGFR inhibitors in non-small cell hmg cancer. Curr Opin Oncol, 2005, 17: 118 - 122.
  • 4Bunn PA Jr, Dziadziuszko R, Varella-Garcia M, et al. Biological markers for non-small cell lung cancer patient selection for epidermal growth factor receptor tyrosine kinase inhibitor therapy. Clin Cancer Res,2006, 12: 3652 - 3656.
  • 5Cappuzzo F, Hirsch FR, Rossi E, et al. Epidennal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell hmg cancer. J Natl Cancer Inst, 2005,97 : 643 - 655.
  • 6Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 2004, 30.4: 1497- 1500.
  • 7Hirsch FR, Varella-Garcia M, Bunn PA Jr, et al. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol,2003,21:3798 - 3807.
  • 8Shigematsu H, Gazdar AF. Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers, Int J Cancer, 2006, 118: 257 - 262.
  • 9Gazdar AF, Minna JD. Inhibition of EGFR signaling: all mutations are not created equal. PLoS Med,2005,2:1085- 1087.
  • 10Tsao MS, Sakurada A, Cutz JC, et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med, 2005, 353: 133- 144.

共引文献4

同被引文献151

引证文献9

二级引证文献35

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部